CIK 0002088082
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Electra Therapeutics, Inc.
Sign in to watch- Ticker
- ETRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 832193635
- Phone
- +1 888-743-2290
- Business address
- 230 EAST GRAND AVENUE, SUITE S-100, SOUTH SAN FRANCISCO, CA, 94080
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market buy Director bought 92,116 shares at an average $8.08 ($744,531)
- 4 Open-market buy Director bought 92,116 shares at an average $8.08 ($744,531)
- 4 Open-market buy Director bought 472,571 shares at an average $7.63 ($3,605,116)
- 4 Open-market buy Director bought 472,571 shares at an average $7.63 ($3,605,116)
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13D Stake Beneficial Ownership Report
- 4 Open-market buy Director bought 1,333,333 shares at $15.00 ($19,999,995)
- 4 Open-market buy Director bought 1,333,333 shares at $15.00 ($19,999,995)
- 3 Insider Initial Statement of Ownership
- 4 Conversion Chief Technical Officer acquired 63,656 shares (conversion)
- 4 Conversion Director acquired 255,635 shares (conversion)
- 4 Conversion Chief Scientific Officer acquired 85,504 shares (conversion)
- 4 Conversion President & CEO acquired 455,484 shares (conversion)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 8-K Event Bylaws or fiscal year change · Other events
Page 1 of 3 · 41 filings